(Q39674037)

13 September 2017

Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo (English)

1 reference

13 September 2017

Diana Azzam

3

0 references

Bryan T. Hennessy

8

object named as

Bryan T Hennessy

1 reference

13 September 2017

Yi Chen

1

1 reference

13 September 2017

Edwin A Alvarez

2

1 reference

13 September 2017

Seth A Wander

4

1 reference

13 September 2017

Natalia Guggisberg

5

1 reference

13 September 2017

Mercè Jordà

6

1 reference

13 September 2017

Zhenlin Ju

7

1 reference

13 September 2017

Joyce M Slingerland

9

1 reference

13 September 2017

language of work or name

English

0 references

publication date

29 July 2010

1 reference

Breast Cancer Research and Treatment

13 September 2017

1 reference

13 September 2017

128

1 reference

13 September 2017

1

1 reference

13 September 2017

69-78

1 reference

https://scigraph.springernature.com/pub.10.1007/s10549-010-1024-7

13 September 2017

0 references

cites work

Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

The relationship between prognostic and predictive factors in the management of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Androgen-stimulated DNA synthesis and cytoskeletal changes in fibroblasts by a nontranscriptional receptor action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Src family kinases and HER2 interactions in human breast cancer cell growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Intracellular signaling pathways: nongenomic actions of estrogens and ligand-independent activation of estrogen receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Pharmacodynamic markers of perifosine efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Non-parametric quantification of protein lysate arrays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Endocrine-responsive breast cancer and strategies for combating resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

10.1007/S10549-010-1024-7

21 January 2018

Identifiers

DOI

1 reference

13 September 2017

1 reference